Molecular Imaging Market is expected to reach US$ 13.09 Billion by 2034 from US$ 8.43 Billion in 2025, with a CAGR of 5.01% from 2026 to 2034. The molecular imaging market is growing due to rising cancer and neurological disease prevalence, increasing adoption of precision medicine, technological advancements in PET and SPECT imaging systems, expanding radiopharmaceutical applications, and growing investments in diagnostic infrastructure across developed and emerging healthcare markets.
The molecular imaging market is experiencing substantial growth due to increasing demand for early and accurate disease diagnosis, particularly in oncology, cardiology, and neurology. Growing adoption of precision medicine and targeted therapies is encouraging healthcare providers to utilize advanced imaging technologies that offer detailed functional insights. Continuous innovations in PET/CT, PET/MRI, and radiopharmaceutical development are enhancing diagnostic accuracy and clinical efficiency. Additionally, rising investments in healthcare infrastructure, expanding research activities in Alzheimer's disease and cancer imaging, and increasing regulatory approvals for advanced imaging systems are supporting market expansion. These factors collectively position molecular imaging as a critical component of modern diagnostic healthcare.
A notable development occurred in June 2024 when Siemens Healthineers received FDA clearance for the Biograph Trinion PET/CT scanner. The system combines high-performance imaging capabilities with energy-efficient operation and supports a broad range of clinical applications, including oncology, cardiology, neurology, and theranostics. Additionally, its lower lifetime operational costs make advanced molecular imaging more accessible to healthcare institutions. As healthcare facilities continue upgrading diagnostic infrastructure, demand for technologically advanced imaging systems is expected to accelerate, creating significant opportunities for market expansion worldwide.
In June 2024, Positron Corporation announced the sale of its Attrius PET System, with installation scheduled during the fourth quarter of 2024. The Attrius platform is specifically designed for nuclear cardiology and delivers high-resolution quantitative imaging capabilities. As one of the few dedicated PET systems developed exclusively for cardiac applications, the technology highlights the growing emphasis on specialized diagnostic solutions. Healthcare providers are increasingly investing in dedicated imaging platforms to improve clinical outcomes and diagnostic precision, supporting sustained growth in the molecular imaging market across cardiovascular care settings.
In January 2025, Lantheus signed a definitive agreement to acquire Life Molecular Imaging for USD 350 million. The acquisition significantly expands Lantheus' Alzheimer's radiodiagnostic portfolio through the addition of advanced PET imaging agents and specialized research capabilities. The transaction reflects increasing industry investment in neurological imaging and highlights the commercial potential of molecular diagnostics in dementia care. As healthcare systems focus on early intervention and precision medicine approaches for neurological disorders, demand for advanced molecular imaging technologies is expected to rise substantially, contributing to long-term market growth.
In March 2025, Telix Pharmaceuticals received FDA approval for Gozellix, a next-generation PSMA-PET imaging agent designed for prostate cancer detection. The approval expanded the range of advanced molecular imaging solutions available to healthcare providers and reinforced the growing role of targeted radiodiagnostics in oncology care. Such innovations are expected to support continued market growth across the United States.
In October 2025, Mediso installed its AnyScan TRIO-TheraMAX SPECT/CT system at Heidelberg University Hospital. The advanced platform was specifically developed for theranostic imaging and targeted radionuclide therapies, enabling improved quantitative imaging and dosimetry capabilities. This development highlights Germany's commitment to adopting next-generation molecular imaging technologies and strengthening its position as a key innovation center within the European diagnostic imaging market.
In February 2026, Wipro GE Healthcare launched the SIGNA Prime Elite, an AI-powered magnetic resonance imaging system manufactured in India. The product incorporates advanced imaging technologies designed to improve workflow efficiency and diagnostic accuracy. Such innovations strengthen India's diagnostic imaging capabilities and support broader adoption of advanced molecular imaging solutions across the country's healthcare sector.
In May 2025, the Ministry of Health introduced advanced PET-CT scanning technology at King Abdullah Medical City in Makkah, marking the first PET-CT system within Ministry of Health facilities in the western region. The launch enhances diagnostic capabilities for oncology, cardiovascular, and neurological disorders while supporting the country's broader healthcare modernization objectives.
Molecular Imaging Industry Overview
Molecular imaging is an advanced diagnostic technique that enables visualization, characterization, and measurement of biological processes at the cellular and molecular levels within the human body. Unlike conventional imaging methods that primarily depict anatomical structures, molecular imaging provides functional information about disease activity, progression, and treatment response. Technologies such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), and hybrid imaging systems are commonly used. Molecular imaging plays a critical role in oncology, cardiology, neurology, and drug development by facilitating early disease detection, accurate diagnosis, personalized treatment planning, and continuous monitoring of therapeutic effectiveness.The molecular imaging market is experiencing substantial growth due to increasing demand for early and accurate disease diagnosis, particularly in oncology, cardiology, and neurology. Growing adoption of precision medicine and targeted therapies is encouraging healthcare providers to utilize advanced imaging technologies that offer detailed functional insights. Continuous innovations in PET/CT, PET/MRI, and radiopharmaceutical development are enhancing diagnostic accuracy and clinical efficiency. Additionally, rising investments in healthcare infrastructure, expanding research activities in Alzheimer's disease and cancer imaging, and increasing regulatory approvals for advanced imaging systems are supporting market expansion. These factors collectively position molecular imaging as a critical component of modern diagnostic healthcare.
Recent Developments in Molecular Imaging Market
- In April 2026, Perceptive Discovery introduced α-Sight, a novel preclinical imaging platform developed to visualize alpha-emitting radiopharmaceuticals in vivo. The technology combines advanced quantitative imaging and radiochemistry capabilities, supporting research into next-generation targeted radiotherapies. The launch demonstrates increasing industry investment in theranostics and precision imaging solutions.
- In March 2026, Lantheus expanded its molecular imaging portfolio through the approval of PYLARIFY TruVu, an advanced formulation of its PSMA PET imaging agent for prostate cancer detection. The new product was developed to improve manufacturing efficiency and supply flexibility, enabling broader patient access to PET imaging services. The launch highlights the growing focus on expanding radiopharmaceutical availability and strengthening diagnostic capabilities in precision oncology.
- In February 2026, Azurity Pharmaceuticals introduced Ferabright, an iron-based MRI contrast agent designed for brain imaging applications. The product enhances visualization of brain lesions and supports improved diagnostic assessment in patients with suspected malignant brain tumors. The launch reflects ongoing innovation in contrast-enhanced molecular and functional imaging technologies aimed at improving diagnostic accuracy.
Growth Drivers for the Molecular Imaging Market
Technological Advancements in PET/CT Imaging Systems
Continuous innovation in imaging technologies is significantly contributing to the growth of the molecular imaging market. Healthcare providers increasingly seek imaging systems that deliver higher image quality, improved diagnostic confidence, and greater operational efficiency. Advanced PET/CT platforms are enabling clinicians to detect diseases at earlier stages while reducing scan times and improving patient outcomes.A notable development occurred in June 2024 when Siemens Healthineers received FDA clearance for the Biograph Trinion PET/CT scanner. The system combines high-performance imaging capabilities with energy-efficient operation and supports a broad range of clinical applications, including oncology, cardiology, neurology, and theranostics. Additionally, its lower lifetime operational costs make advanced molecular imaging more accessible to healthcare institutions. As healthcare facilities continue upgrading diagnostic infrastructure, demand for technologically advanced imaging systems is expected to accelerate, creating significant opportunities for market expansion worldwide.
Rising Demand for Specialized Cardiac Imaging Solutions
The increasing prevalence of cardiovascular diseases is driving demand for dedicated molecular imaging systems capable of delivering highly accurate cardiac assessments. Molecular imaging technologies provide valuable information regarding myocardial perfusion, cardiac function, and disease progression, supporting informed treatment decisions and improved patient management.In June 2024, Positron Corporation announced the sale of its Attrius PET System, with installation scheduled during the fourth quarter of 2024. The Attrius platform is specifically designed for nuclear cardiology and delivers high-resolution quantitative imaging capabilities. As one of the few dedicated PET systems developed exclusively for cardiac applications, the technology highlights the growing emphasis on specialized diagnostic solutions. Healthcare providers are increasingly investing in dedicated imaging platforms to improve clinical outcomes and diagnostic precision, supporting sustained growth in the molecular imaging market across cardiovascular care settings.
Expanding Investments in Alzheimer's Disease Diagnostics
The growing burden of neurodegenerative disorders is creating strong demand for advanced molecular imaging solutions capable of detecting disease-specific biomarkers. PET imaging plays an essential role in identifying amyloid plaques and other neurological abnormalities associated with Alzheimer's disease, supporting earlier diagnosis and treatment planning.In January 2025, Lantheus signed a definitive agreement to acquire Life Molecular Imaging for USD 350 million. The acquisition significantly expands Lantheus' Alzheimer's radiodiagnostic portfolio through the addition of advanced PET imaging agents and specialized research capabilities. The transaction reflects increasing industry investment in neurological imaging and highlights the commercial potential of molecular diagnostics in dementia care. As healthcare systems focus on early intervention and precision medicine approaches for neurological disorders, demand for advanced molecular imaging technologies is expected to rise substantially, contributing to long-term market growth.
Challenges in the Molecular Imaging Market
High Equipment and Operational Costs
The molecular imaging market faces challenges associated with the substantial costs of advanced imaging systems and supporting infrastructure. PET, SPECT, and hybrid imaging technologies require significant capital investment, specialized facilities, and highly trained personnel. Additionally, the production, transportation, and storage of radiopharmaceuticals add further operational expenses. These financial requirements can limit adoption among smaller healthcare facilities and institutions in developing regions. Budget constraints and reimbursement limitations may also delay technology upgrades. Consequently, high ownership and maintenance costs remain a major barrier to broader market penetration despite the growing clinical value of molecular imaging technologies.Regulatory and Radiopharmaceutical Supply Constraints
The molecular imaging industry depends heavily on radiopharmaceutical availability and regulatory compliance. The development and approval of new imaging agents often involve lengthy clinical validation processes and stringent regulatory requirements. Furthermore, many radiotracers have short half-lives, requiring efficient production and distribution networks. Any disruption in isotope supply chains can affect imaging service availability and delay patient diagnosis. Regulatory complexities related to radioactive materials also increase operational challenges for healthcare providers and manufacturers. These factors may restrict market expansion, particularly in regions where radiopharmaceutical production infrastructure remains underdeveloped or access to specialized facilities is limited.United States Molecular Imaging Market
The United States remains the largest molecular imaging market globally, supported by advanced healthcare infrastructure, strong reimbursement systems, and widespread adoption of precision medicine. Growing demand for early cancer detection, neurological disease diagnosis, and theranostic applications continues to drive investments in PET and SPECT imaging technologies. The country also benefits from a robust radiopharmaceutical development ecosystem and ongoing clinical research activities.In March 2025, Telix Pharmaceuticals received FDA approval for Gozellix, a next-generation PSMA-PET imaging agent designed for prostate cancer detection. The approval expanded the range of advanced molecular imaging solutions available to healthcare providers and reinforced the growing role of targeted radiodiagnostics in oncology care. Such innovations are expected to support continued market growth across the United States.
Germany Molecular Imaging Market
Germany is a leading European molecular imaging market, driven by strong healthcare expenditure, advanced diagnostic infrastructure, and increasing adoption of nuclear medicine technologies. The country continues to invest in precision diagnostics to improve outcomes in oncology, neurology, and cardiovascular disease management. Growing research activity in theranostics and radiopharmaceutical development is further supporting market expansion.In October 2025, Mediso installed its AnyScan TRIO-TheraMAX SPECT/CT system at Heidelberg University Hospital. The advanced platform was specifically developed for theranostic imaging and targeted radionuclide therapies, enabling improved quantitative imaging and dosimetry capabilities. This development highlights Germany's commitment to adopting next-generation molecular imaging technologies and strengthening its position as a key innovation center within the European diagnostic imaging market.
India Molecular Imaging Market
India's molecular imaging market is expanding rapidly due to rising cancer incidence, growing awareness of early disease diagnosis, and increasing investments in healthcare infrastructure. The adoption of advanced imaging technologies is accelerating across major hospitals and diagnostic centers, particularly in urban regions. Growing demand for precision medicine and improved access to radiological services are supporting market development.In February 2026, Wipro GE Healthcare launched the SIGNA Prime Elite, an AI-powered magnetic resonance imaging system manufactured in India. The product incorporates advanced imaging technologies designed to improve workflow efficiency and diagnostic accuracy. Such innovations strengthen India's diagnostic imaging capabilities and support broader adoption of advanced molecular imaging solutions across the country's healthcare sector.
Saudi Arabia Molecular Imaging Market
Saudi Arabia is witnessing significant growth in the molecular imaging market due to increasing healthcare investments, expanding nuclear medicine infrastructure, and the implementation of Vision 2030 healthcare transformation initiatives. Rising cancer incidence and growing demand for early disease detection are encouraging healthcare providers to adopt advanced PET and SPECT imaging technologies. The government continues to invest in modern diagnostic equipment to improve healthcare quality and patient outcomes.In May 2025, the Ministry of Health introduced advanced PET-CT scanning technology at King Abdullah Medical City in Makkah, marking the first PET-CT system within Ministry of Health facilities in the western region. The launch enhances diagnostic capabilities for oncology, cardiovascular, and neurological disorders while supporting the country's broader healthcare modernization objectives.
Single Photon Emission Computed Tomography (SPECT) Market
The Single Photon Emission Computed Tomography (SPECT) segment represents a significant component of the molecular imaging market due to its widespread use in oncology, cardiology, and neurology applications. SPECT imaging enables healthcare professionals to evaluate physiological and biochemical processes, supporting early disease detection and treatment monitoring. The technology offers advantages such as broad radiotracer availability, cost-effectiveness, and integration with computed tomography through hybrid SPECT/CT systems. Increasing demand for functional imaging and the growing prevalence of chronic diseases are driving adoption across hospitals and diagnostic centers. Technological advancements in detector design, image reconstruction software, and quantitative imaging capabilities are further improving diagnostic accuracy, positioning the SPECT segment for sustained growth within the global molecular imaging market.Cardiovascular Molecular Imaging Market
The cardiovascular molecular imaging segment is gaining importance within the molecular imaging market due to the increasing global burden of heart disease and related disorders. Molecular imaging techniques, particularly PET and SPECT, enable detailed assessment of myocardial perfusion, cardiac metabolism, inflammation, and tissue viability. These capabilities support early diagnosis and improved management of coronary artery disease, heart failure, and other cardiovascular conditions. Growing demand for non-invasive diagnostic procedures and personalized treatment strategies is accelerating adoption among healthcare providers. Furthermore, advancements in dedicated cardiac imaging systems and novel radiotracers are enhancing image quality and clinical utility. As healthcare systems emphasize preventive cardiology and early intervention, cardiovascular molecular imaging is expected to witness strong demand throughout the forecast period.Hospitals Molecular Imaging Market
Hospitals constitute the largest end-user segment in the molecular imaging market owing to their comprehensive diagnostic capabilities, advanced infrastructure, and access to specialized medical professionals. These facilities routinely utilize PET, SPECT, PET/CT, and PET/MRI systems for the diagnosis and management of cancer, neurological disorders, cardiovascular diseases, and other chronic conditions. Rising patient volumes and increasing demand for precision medicine are encouraging hospitals to invest in advanced molecular imaging technologies and radiopharmaceutical capabilities. Additionally, the integration of artificial intelligence, digital imaging platforms, and hybrid imaging systems is enhancing workflow efficiency and diagnostic confidence. Growing investments in healthcare infrastructure worldwide are expected to further strengthen the role of hospitals as primary users of molecular imaging solutions.Molecular Imaging Market Segmentation
Modality
- Single Photon Emission Computed Tomography
- Psitron Emmission Tomography
- Nuclear Magnetic Resonance Spectrometer
- Molecular Utrasound Imaging
- Others
Application
- Oncology
- Cardiovascular
- Neurology
- Respiratory
- Gastrointestinal
End Use
- Hospitals
- Diagnostic Imaging Centers
- Research Institutes
Countries
North America
- United States
- Canada
Europe
- France
- Germany
- Italy
- Spain
- United Kingdom
- Belgium
- Netherlands
- Turkey
Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Malaysia
- Indonesia
- Australia
- New Zealand
Latin America
- Brazil
- Mexico
- Argentina
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
All the Key players have been covered with 5 Viewpoints
- Overviews
- Key Person
- Recent Developments
- SWOT Analysis
- Revenue Analysis
Key Players Analysis
- GE HealthCare
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- Shimadzu Corp
- United Imaging Healthcare Co., Ltd.
- Bruker Corp
- FUJIFILM Holdings Corp
- Cubresa Inc.
Table of Contents
1. Introduction3. Executive Summary5. Molecular Imaging Market13. Merger and Acquisition
2. Research & Methodology
4. Market Dynamics
6. Market Share Analysis
7. Modality - Historical and Current Market Trends & Forecast
8. Application - Historical and Current Market Trends & Forecast
9. End Use - Historical and Current Market Trends & Forecast
10. Countries - Historical and Current Market Trends & Forecast
11. Porter’s Five Forces Analysis
12. SWOT Analysis
14. Key Players Analysis
Companies Mentioned
- GE HealthCare
- Siemens Healthineers AG
- Koninklijke Philips N.V.
- Shimadzu Corp
- United Imaging Healthcare Co., Ltd.
- Bruker Corp
- FUJIFILM Holdings Corp
- Cubresa Inc.
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | June 2026 |
| Forecast Period | 2025 - 2034 |
| Estimated Market Value ( USD | $ 8.43 Billion |
| Forecasted Market Value ( USD | $ 13.09 Billion |
| Compound Annual Growth Rate | 5.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 8 |
